Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Pedro C. Barata"'
Autor:
Chaim Domb, Jorge A. Garcia, Pedro C. Barata, Prateek Mendiratta, Santosh Rao, Jason R. Brown
Publikováno v:
Therapeutic Advances in Urology, Vol 16 (2024)
Antibody-drug conjugates and bicycle toxin conjugates represent a tremendous advance in drug delivery technology and have shown great promise in the treatment of urothelial cancer. Previously approved systemic therapies, including chemotherapy and im
Externí odkaz:
https://doaj.org/article/350bbe2e3f5a42dab1d27fcb86ff9b54
Autor:
Albert Jang, Jake N. Lichterman, Jeffrey Y. Zhong, Jonathan E. Shoag, Jorge A. Garcia, Tian Zhang, Pedro C. Barata
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
ABSTRACTRenal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory ap
Externí odkaz:
https://doaj.org/article/0b93a94ec1ea4b5bbf631a0170fc8c8a
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 4246-4256 (2023)
The therapeutic landscape of several genitourinary malignancies has been revolutionized by the development of immune checkpoint inhibitors (ICIs); however, the utility of immunotherapies in prostate cancer has been limited, partly due to the immunolo
Externí odkaz:
https://doaj.org/article/52d8e5ded7684469971dc8a5c6e36a6f
Autor:
Umang Swami, Raquel Mae Zimmerman, Roberto H. Nussenzveig, Edgar Javier Hernandez, Yeonjung Jo, Nicolas Sayegh, Sergiusz Wesolowski, Lesli A. Kiedrowski, Pedro C. Barata, Gordon Howard Lemmon, Mehmet A. Bilen, Elisabeth I. Heath, Lakshminarayan Nandagopal, Hani M. Babiker, Sumanta K. Pal, Michael Lilly, Benjamin L. Maughan, Benjamin Haaland, Mark Yandell, Oliver Sartor, Neeraj Agarwal
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differenti
Externí odkaz:
https://doaj.org/article/4e03b0f2c01f46158e4c977641bd2a04
Autor:
Jacob W. Greenberg, Hogyoung Kim, Ahmed A. Moustafa, Amrita Datta, Pedro C. Barata, A. Hamid Boulares, Asim B. Abdel-Mageed, Louis S. Krane
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors. There are limited curable treatments available for metastatic ccRCC because this disease is unresponsi
Externí odkaz:
https://doaj.org/article/8bcce53528064b139c18bf1570a9c148
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100639- (2022)
Papillary renal cell carcinoma (PRCC) is the most common subtype of non-clear cell renal cell carcinoma. PRCC can be subdivided into types 1 and 2 based on histology, each associated with different genetic mutations. The MET gene is commonly altered
Externí odkaz:
https://doaj.org/article/4787e69ec5a84544938681a1307ea562
Publikováno v:
Therapeutic Advances in Urology, Vol 13 (2021)
Immune checkpoint inhibition has been approved for front-line treatment of metastatic bladder cancer in patients who are cisplatin-ineligible and demonstrate programmed death-ligand 1 (PD-L1) positivity. This approval followed the positive results of
Externí odkaz:
https://doaj.org/article/aab5e206a2e94c8296f1ec2824c15d33
Autor:
Ulkuhan I. Koksal, Janeiro Valle Goffin, Brian Lewis, Oliver A. Sartor, Elizaveta Belyaeva, Francisco Socola, Pedro C. Barata
Publikováno v:
Case Reports in Hematology, Vol 2020 (2020)
Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). This agent is approved as monotherapy or in combination with immune checkpoint inhibitors for the treatment o
Externí odkaz:
https://doaj.org/article/9fa7166197724943bfc39e13b60afd77
Autor:
Marcus Moses, MS, Alex Niu, MD, Michael B. Lilly, MD, Andrew W. Hahn, MD, Roberto Nussenzveig, PhD, Elisa Ledet, PhD, Charlotte Manogue, MPH, Patrick Cotogno, MSPH, Brian Lewis, MD, MPH, Jodi Layton, MD, Neeraj Agarwal, MD, Oliver Sartor, MD, Pedro C. Barata, MD, MSc
Publikováno v:
Cancer Treatment and Research Communications, Vol 24, Iss , Pp 100193- (2020)
Background: The crossover from abiraterone acetate (AA) to enzalutamide (ENZA) is a frequent approach in clinical practice. Our aim was to explore the role of genomic alterations as putative biomarkers of response to sequential AA followed by ENZA in
Externí odkaz:
https://doaj.org/article/91c96b47cba746c491c1996c235c077a
Autor:
Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia, Brian I. Rini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. Methods A retrospective analysis o
Externí odkaz:
https://doaj.org/article/f6ec2bd029234b5785f346286c3599fb